Sex differences in clinical characteristics and inpatient outcomes among 2442 hospitalized Chinese patients with nonvalvular atrial fibrillation:The Nanchang Atrial Fibrillation Project by Xiong, Qinmei et al.
 
 
Sex differences in clinical characteristics and
inpatient outcomes among 2442 hospitalized
Chinese patients with nonvalvular atrial fibrillation
Xiong, Qinmei; Shantsila, Alena; Lane, Deirdre; Zhou, Qiongqiong; Liu, Ying; Shen, Yang;
Cheng, Xiaoshu; Hong, Kui; Lip, Gregory
DOI:
10.1016/j.ijcard.2015.08.076
License:
Creative Commons: Attribution-NonCommercial-NoDerivs (CC BY-NC-ND)
Document Version
Peer reviewed version
Citation for published version (Harvard):
Xiong, Q, Shantsila, A, Lane, D, Zhou, Q, Liu, Y, Shen, Y, Cheng, X, Hong, K & Lip, GYH 2015, 'Sex differences
in clinical characteristics and inpatient outcomes among 2442 hospitalized Chinese patients with nonvalvular
atrial fibrillation: The Nanchang Atrial Fibrillation Project', International Journal of Cardiology, vol. 201, pp. 195-9.
https://doi.org/10.1016/j.ijcard.2015.08.076
Link to publication on Research at Birmingham portal
General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the
copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes
permitted by law.
•	Users may freely distribute the URL that is used to identify this publication.
•	Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private
study or non-commercial research.
•	User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?)
•	Users may not further distribute the material nor use it for the purposes of commercial gain.
Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
When citing, please reference the published version.
Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been
uploaded in error or has been deemed to be commercially or otherwise sensitive.
If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to
the work immediately and investigate.
Download date: 01. Feb. 2019
  	

Sex differences in clinical characteristics and inpatient outcomes amongst
2442 hospitalized Chinese patients with nonvalvular atrial fibrillation: The
Nanchang Atrial Fibrillation Project
Qinmei Xiong, Alena Shantsila, Deirdre A. Lane, Qiongqiong Zhou,
Ying Liu, Yang Shen, Xiaoshu Cheng, Kui Hong, Gregory Y.H. Lip
PII: S0167-5273(15)30304-1
DOI: doi: 10.1016/j.ijcard.2015.08.076
Reference: IJCA 21030
To appear in: International Journal of Cardiology
Received date: 4 June 2015
Revised date: 4 August 2015
Accepted date: 6 August 2015
Please cite this article as: Xiong Qinmei, Shantsila Alena, Lane Deirdre A., Zhou
Qiongqiong, Liu Ying, Shen Yang, Cheng Xiaoshu, Hong Kui, Lip Gregory Y.H., Sex
diﬀerences in clinical characteristics and inpatient outcomes amongst 2442 hospitalized
Chinese patients with nonvalvular atrial ﬁbrillation: The Nanchang Atrial Fibrillation
Project, International Journal of Cardiology (2015), doi: 10.1016/j.ijcard.2015.08.076
This is a PDF ﬁle of an unedited manuscript that has been accepted for publication.
As a service to our customers we are providing this early version of the manuscript.
The manuscript will undergo copyediting, typesetting, and review of the resulting proof
before it is published in its ﬁnal form. Please note that during the production process
errors may be discovered which could aﬀect the content, and all legal disclaimers that
apply to the journal pertain.
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
1 
 
Sex differences in clinical characteristics and inpatient outcomes amongst 2442 
hospitalized Chinese patients with nonvalvular atrial fibrillation: The Nanchang 
Atrial Fibrillation Project 
 
Qinmei Xiong1,2, Alena Shantsila2, Deirdre A Lane2, Qiongqiong Zhou1, Ying Liu1, Yang 
Shen1, Xiaoshu Cheng1, Kui Hong1*, Gregory Y H Lip2* 
1 Cardiovascular Department, the Second Affiliated Hospital of Nanchang University, 
Nanchang, China; 2University of Birmingham Centre for Cardiovascular Sciences, City 
Hospital, Birmingham, United Kingdom; 
[*Joint senior authors] 
 
Correspondence to:   Prof GYH Lip 
Tel +44 121 507 5080; Fax: +44 121 554 4083; g.y.h.lip@bham.ac.uk (GYH Lip) 
  
  
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
2 
 
ABSTRACT 
Background  Limited data exists on the impact of sex on clinical characteristics and 
outcomes amongst nonvalvular AF patients from China. We investigated the impact of 
gender on risk factors and inpatient mortality in a hospitalised nonvalvular AF cohort in 
Nanchang, China. 
Methods We studied consecutive patients hospitalised with nonvalvular AF between 
May 2011 and December 2013. Predictors of inpatient mortality were evaluated using 
multivariate regression analyses. 
Results We studied 2,442 patients (43.7% female; mean age 71.8), with a median 
hospital stay of 10 days (IQR: 7-14). Inpatient mortality was 2.2%. Mean age, CHADS2 
and CHA2DS2-VASc scores were higher in females vs. males (all p<0.0001). Oral 
anticoagulation use during hospitalization was 33.3% without sex differences, and 
length of stay and inpatient outcomes were comparable between sexes.  
On multivariate analyses, the significant risk factors of inpatient death in females were 
previous ischemic stroke/transient ischemic attack (TIA)/thromboembolism (TE) 
(Odds Ratio (OR): 2.27; 95% Confidence Intervals (CI): 1.43-3.61), peripheral artery 
disease (OR: 5.75, 95% CI: 1.49-22.16) and chronic renal disease (OR: 5.68, 95% CI: 
1.46-22.13). Among males, only age (OR: 1.06, 95% CI: 1.02-1.11) and previous 
ischemic stroke/TIA/TE (OR: 1.81, 95% CI: 1.25-2.63) were independent predictors of 
inpatient mortality. 
Conclusion  Sex related differences in clinical characteristics and stroke risk profile were 
evident in Chinese nonvalvular AF patients, but no sex disparity was evident in the low 
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antithrombotic therapy use or inpatient mortality. Previous ischemic stroke/TIA/TE 
was an important predictor of inpatient mortality in both female and male patients. 
 
KEY WORDS: Atrial fibrillation; Inpatient mortality; Oral anticoagulation; Sex  
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INTRODUCTION 
Atrial fibrillation (AF) is the most common heart rhythm disorder and the global burden 
of AF and its high risk of stroke are well documented in both Western and Asia 
countries [1-4]. Findings from the prospective community-based Rotterdam study 
demonstrate that the number of AF patients aged >55 years old will be more than 
double to 17.9 million in European Union from 2010 to 2060[5]. An investigation in the 
southwest of China has shown that the prevalence of AF had increased 20-fold over an 
11-year period, while AF-related stroke increased 13-fold[4]. Due to the increasing 
epidemic of AF with an aging population, AF burden has become a growing public health 
concern worldwide. 
In recent years, sex related differences in incidence, presentations, outcomes and 
clinical management among patients with nonvalvular AF have been demonstrated in 
previous epidemiologic studies from Western countries[6, 7], with a greater prevalence 
of AF usually among males, while female patients are at higher risk of stroke and 
thromboembolism[8].  
Indeed, females with AF tended to be older and sicker, with a worse cardiovascular risk 
profile and a lower quality of life [9].  In the original Framingham cohort, for example, 
AF was associated with a 1.9 fold higher risk of death among female patients compared 
to males [10]. The Anticoagulation and Risk factors In Atrial fibrillation (ATRIA) cohort 
prospectively studied 13 559 AF patients and have shown that females were at 1.6 fold 
higher risk for AF-related thromboembolism than males [11]. The increased risk of 
stroke among females with AF can be further demonstrated by a systemic review and 
meta-analysis [8]. Due to the higher risk of stroke among females AF patients, female 
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sex has been incorporated in CHA2DS2-VASc score as a risk factor of stroke or systemic 
embolism among AF patients[12].  
However, most sex-related investigations of AF are based on data from Western 
populations [8], whilst few studies have investigated the impact of sex on clinical 
characteristics and inpatient outcomes amongst nonvalvular AF patients from China.  
Hence, the aim of this study was to investigate sex-related differences in clinical 
characteristics and inpatient outcomes amongst a hospitalised cohort of Chinese 
nonvalvular AF patients, in the Nanchang Atrial Fibrillation Project. 
 
METHODS 
Study population 
All consecutive patients with nonvalvular AF admitted to our tertiary care hospital, the 
second affiliated hospital of Nanchang university, from May 2011 till December 2013, 
were included. This is a teaching hospital which covers the health management of a 
population of over 5 million. Patients admitted with a concomitant diagnosis of AF were 
eligible for inclusion in this registry. Those with AF combined with the presence of 
valvular heart disease requiring management were excluded. The diagnosis of AF was 
made by the attending physician confirmed with an electrocardiogram or Holter 
monitor.   
Data collection 
The demographic and clinical characteristics of included patients were extracted from 
our hospital electronic data system, including date of birth, sex, length of stay, diagnoses 
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and death prior to discharge. Medical records were reviewed by hospital personnel to 
determine the following data: current smoking; weight and height; systolic and diastolic 
blood pressure (BP) levels on admission; laboratory data during hospitalization; 
concomitant diseases; oral anticoagulant therapy before admission and during 
hospitalization. Both CHADS2 (one point each for congestive heart failure, hypertension, 
age >=75 years, diabetes; two points for previous stroke/transient ischemic attack 
(TIA)/Thromboembolism(TE)) and CHA2DS2-VASc (one point each for systolic heart 
failure, hypertension, age 65-74 years, diabetes, vascular disease and female sex; two 
points each for age ≥75 years and previous stroke/TIA/TE) scores were calculated to 
assess the risk of stroke and thromboembolism[12, 13].    
Definitions 
Inpatient ischemic stroke was defined as a focal neurologic deficit of sudden onset 
newly diagnosed by a neurologist and confirmed by CT or MRI. Inpatient major bleeding 
was defined as intracranial or gastrointestinal haemorrhage which was newly 
diagnosed during the current admission. Inpatient death was defined as death from any 
cause occurring during hospitalization. Length of hospital stay was calculated as the 
number of nights spent in hospital.   
Heart failure was defined as the presence of signs and symptoms of either right or left 
ventricular dysfunction, or both,  confirmed by left ventricular ejection fraction (LVEF) 
<40%, documented by echocardiogram, or NYHA classification class ≥II. All other 
concomitant diseases were collected on the basis of the medical notes, including 
hypertension, diabetes, coronary artery disease, peripheral artery disease, 
cardiomyopathy, chronic renal disease, hyperthyroidism and cancer. Any discrepancies 
were resolved by rechecking the medical records.   
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Statistical analysis 
All analyses were performed using the IBM SPSS Version 21.0 (SPSS, Inc., Chicago, IL). 
The distribution of continuous variables was examined by the Kolmogorov-Smirnov test. 
Normally distributed variables are presented as mean (standard deviation, SD) and 
analysed by t-test, while the non-normally distributed are presented as median with 
interquartile range (IQR) and analysed by Mann-Whitney U-test. Categorical variables 
are presented as n (%) and analysed using Chi-square test or a Fisher’s exact test. 
Univariate and multivariate logistic regression analyses were performed to evaluate the 
risk factors associated with inpatient death amongst both males and females. Variables 
for the multivariable logistic regression model included age, heart failure, hypertension, 
diabetes, previous ischemic stroke/TIA/TE, coronary artery disease, peripheral artery 
disease, and chronic kidney disease. The variables were selected after performing a 
univariate regression analysis first and then choosing those variables with a P value ≤ 
0.2 as candidates for multivariate analysis. A two-sided p<0.05 was considered 
statistically significant.   
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RESULTS  
 
In total, 3327 AF patients were admitted between May 2011 and December 2013. Of 
these, 875 (26.3%) were excluded due to the presence of valvular heart disease 
requiring management, and 10 were excluded for insufficient basic clinical data, leaving 
a final cohort population of 2442 non-valvular AF patients (Figure 1). Of the whole 
cohort, there were 1453 patients hospitalised in the cardiovascular department, and 
1030 patients admitted with a primary or secondary diagnosis of AF.  
 
Males were more prevalent than females (56.3% vs 43.7%, P<0.0001). Other 
demographic and clinical characteristics are summarized in Table 1. Overall mean±SD 
age was 70.6±11.3 years, with females being significantly older (p<0.0001) and with 
more females aged ≥75 years (45.7% vs 39.8%; p=0.001). Body mass index (BMI) was 
similar, but current smoking was more common in males Females had higher systolic 
BP on admission (p<0.0001). Among the 1830 (74.9%) patients with LVEF assessed, 
almost three-quarters of the females had LVEF ≥ 55% and a significantly higher mean 
LVEF value (p<0.0001).    
 
Concomitant diseases 
There were no significant sex differences in the subtypes of AF (p=0.13). Hypertension 
and heart failure were the most common concomitant diseases among the whole cohort. 
As shown in Table 1, females had a significantly higher prevalence of hypertension, 
diabetes, and hyperthyroidism, but a lower prevalence of coronary artery disease, 
cardiomyopathy, chronic renal disease, and cancer than males.   
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CHA2DS2-VASc and CHADS2 scores 
Both the median CHA2DS2-VASc and CHADS2 scores were higher in female AF patients 
(p<0.0001) (see Table 2). When those patients with CHADS2 of 0 or 1 were further 
refined using CHA2DS2-VASc score, more female patients were classified into the group 
of CHA2DS2-VASc ≥2 (p=0.009).  
 
Medication therapy at discharge 
Among the 2389 (97.8%) patients discharged alive, there were low proportions of 
patients with intervention therapy such as catheter ablation or pacemakers, 3.0% and 
2.2%, respectively (Table 3). No sex differences were evident.  More female patients 
received angiotensin receptor blockers (ARB) and calcium channel blockers (CCB), but 
there were no statistical differences in other drugs.    
 
Antithrombotic therapy 
Only 173 (7.3%) patients received warfarin prior to admission; this increased to 791 
(33.3%) during hospitalization (see Table 3). No information on quality of 
anticoagulation control, as reflected by time in therapeutic range (TTR) was recorded.  
Rates of aspirin or clopidogrel use at discharge were 38.9% and 10.7%, respectively. No 
sex differences were evident in the choice of antithrombotic therapy.   
 
Inpatient outcomes 
Fifty-three (2.2%) patients died during hospitalization, with no sex differences (see 
Table 4). The incidence rates of inpatient ischaemic stroke or major bleeding were 11.6% 
and 3.3%, respectively.  Median (IQR) length of stay was 10 (7-14) days.  There were no 
sex differences in these inpatient outcomes.    
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On multivariate analyses (see Table 5), the risk factors significantly associated with 
inpatient death in females were previous ischemic stroke/TIA/TE (OR: 2.27; 95% CI: 
1.43-3.61), peripheral artery disease (OR: 5.75, 95% CI: 1.49-22.16) and chronic renal 
disease (OR: 5.68, 95% CI: 1.46-22.13). Hypertension was found to be associated with a 
lower risk of inpatient death in females (OR: 0.35, 95% CI: 0.14-0.88).    
 
Among males, only age (OR: 1.06, 95% CI: 1.02-1.11) and previous ischemic 
stroke/TIA/TE (OR: 1.81, 95%CI: 1.25-2.63) were independent predictors of inpatient 
mortality.   
 
 
 
DISCUSSION 
 
Since there is some evidence that AF patients from Asian cohorts are at particularly high 
risk of adverse outcomes, further information is needed on their clinical epidemiology. 
In the present study, sex-related differences in clinical characteristics and stroke risk 
profile were evident in Chinese nonvalvular AF patients. Compared with males, females 
patients were significantly older with higher CHADS2 and CHA2DS2-VASc scores. 
Hypertension, diabetes, and hyperthyroidism were more commonly found with AF in 
females, but males had a higher prevalence of concomitant diseases including coronary 
artery disease, cardiomyopathy, chronic renal disease, and cancer. Previous ischemic 
stroke/TIA/TE was an important predictor of inpatient mortality in both males and 
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females. However, no sex disparity was evident in the low antithrombotic therapy use in 
this Chinese hospital-based cohort or inpatient mortality.    
 
Consistent with previous studies on other populations [9, 14], our analyses shows that 
more of the patients admitted with AF were male, but that female AF patients were 
significantly older with a higher proportion in the elderly group (≥75 years), which can 
perhaps be explained by the longer life expectancy for females. The higher incidence of 
AF in males and the older age in females is also consistent with a study from Southwest 
of China[4] but contrasts with a recent cross-sectional study in rural China which 
reported no significant sex differences at any age [15]. The discrepancy in these findings 
may be due the study setting and patient demography from different districts.   
 
Female AF patients tended to be more symptomatic and may be more likely to seek 
medical attention as a result [9]. However, there was no impact of sex on antithrombotic 
therapy.  The use of warfarin prior to admission was sub-optimal, with only 7.3% 
receiving warfarin. This figure increased to 33.3% during hospitalization, with no sex 
differences evident.   
 
These data can be further reinforced by the data from a prospective multicentre 
international observational registry, which demonstrates the comparable anticoagulant 
use in males and females overall (60.9% versus 60.8%) [16]. However, among those 
patients with CHA2DS2-VASc score of ≥2, 64.6% of males versus 61.6% of females 
received anticoagulant therapy in this global registry, with combination therapy with 
anticoagulant plus antiplatelet more frequently used in males. Another study based on 
data from 11 general practices in Darlington in the UK found more females who were 
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not receiving anticoagulants, with a higher risk of stroke, compared with males [17].    
The low overall use of warfarin is compounded by lack of recorded information on TTR, 
which has been closely related to the efficacy and safety related to warfarin; current 
guidelines recommend a TTR of >70%[18, 19].  None of our patients were using the 
non-Vitamin K oral anticoagulants (NOACs), and whether their subsequent widespread 
introduction would improve anticoagulation uptake remains uncertain. 
 
Sex differences in the risk of thromboembolism and death have been shown among AF 
patients in several large Scandinavian nationwide cohort studies [20-23]. Female sex 
has been established as a risk factor for thromboembolism and death among AF patients, 
and incorporated in the CHA2DS2-VASc score. Nonetheless, whether female sex per se is 
intrinsically associated with higher thromboembolic events has been debated. In a 
Danish study, a lower stroke risk was identified for females in relatively young patients 
with AF[22]. According to the current results, both CHA2DS2-VASc and CHADS2 scores 
were higher in female patients, indicating greater risk of stroke for females than males. 
Regardless of female sex as a risk factor, the higher CHA2DS2-VASc scores were 
observed among female patients, as reflected by more females with score of ≥3 than 
males with score of ≥2. Additionally, more female patients with CHADS2 of 0 or 1 were 
identified to have higher risk of stroke, presented with CHA2DS2-VASc of ≥ 2. Hence, our 
data may further support the greater risk of thromboembolic events among female AF 
patients.  
 
For inpatient outcomes, no significant sex differences were found. The incidence of 
inpatient death and inpatient ischemic stroke was comparable between males and 
females. Previous ischemic stroke/TIA/TE was independently associated with 
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increased inpatient mortality for both males and females. In addition, older age was 
associated with higher risk of inpatient death among men, while PAD and chronic renal 
disease were independent predictors of inpatient mortality for females.  
Our data also show that female AF patients with hypertension had a lower risk of 
inpatient death, a finding that was not consistent with the traditional conception. One 
possible explanation is the underdiagnosis of hypertension among female patients and 
those with hypertension were well-treated with antihypertensive drugs which can 
protect patients from death.  However, a slightly higher mean systolic BP was seen 
amongst females and the mortality observation could also be a chance finding or 
residual confounding. 
 
Limitations 
There are several limitations to be addressed in the present study. Firstly, the data was 
extracted based on medical records from a single centre, which may not be 
generalizable to the whole population of China. Secondly, AF was not the primary or 
secondary cause for admission in 1412 (57.8%) patients. Third, only risk factors 
associated with inpatient mortality were analyzed for both males and females.  Finally, 
all included patients were admitted to various departments, not limited to 
cardiovascular department.   
 
In conclusion, sex related differences were evident in clinical characteristics and stroke 
risk profile among Chinese patients with nonvalvular AF. Previous ischemic 
stroke/TIA/TE was an important predictor of inpatient mortality in both males and 
females. However, no sex disparity was evident in the low antithrombotic therapy use 
or inpatient mortality. 
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Table 1. Baseline characteristics of the 2442 AF patients   
N (%) Total Males Females  P value 
No. of subjects 2442 1376(56.3) 1066(43.7) <0.0001 
Age 
Mean±SD (years) 70.6±11.3 69.6±11.8 71.8±10.4 <0.0001 
<65 636 (26.0) 397 (28.9) 239(22.4) 
0.001 65-74 772 (31.6) 432 (31.4) 340 (31.9) 
≥75 1034 (42.3) 547 (39.8) 487 (45.7) 
Body mass index, n=1150* 
mean±SD (kg/m2)  23.5±3.9 23.6±3.4 23.4±4.4 0.53 
Smoking status 
Never/Former 2078(85.1) 1035(75.2) 1043(97.8) 
<0.0001 
Current 364(14.9) 341(24.8) 23(2.2) 
Blood pressure on admission, n=2424* 
SBP, mean±SD (mmHg) 131.3±21.4 129.9±21.2 133.1±21.5 <0.0001 
DBP, mean±SD (mmHg) 78.4±13.0 78.2±12.9 78.7±13.2 0.36 
LVEF, n=1830* 
mean±SD  58.7±11.7 57.6±12.0 60.0±11.2 <0.0001 
<55% 537 (29.3) 332(32.7) 205(25.2) <0.0001 
≥55% 1293(70.7) 683(67.3) 610(74.8) 
Type of AF 
Paroxysmal 357 (14.6) 188(13.7) 169(15.9) 
0.13 
Persistent/Permanent  2085 (85.4) 1188(86.3) 897(84.1) 
Concomitant Conditions 
Previous Ischemic 
stroke/TIA/TE 
624(25.6) 347(25.2) 277(26.0) 0.67 
Heart failure 872(35.7) 474(34.4) 398(37.3) 0.15 
Hypertension 1375(56.3) 730(53.1) 645(60.5) <0.0001 
Diabetes 223(9.1) 108(7.8) 115(10.8) 0.01 
CAD 467(19.1) 307(22.3) 160(15.0) <0.0001 
PAD 86(3.5) 49(3.6) 37(3.5) 1.00 
Cardiomyopathy 169 (6.9) 118 (8.6) 51 (4.8) <0.0001 
Chronic Kidney  disease  140 (5.7) 94 (6.8) 46 (4.3) 0.01 
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Hyperthyroidism 125 (5.1) 59 (4.3) 66 (6.2) 0.04 
Cancer 142 (5.8) 97 (7.0) 45 (4.2) 0.003 
AF, atrial fibrillation; CAD, Coronary artery disease; DBP, diastolic blood pressure; LVEF, 
left ventricular ejection fraction; PAD, Peripheral artery disease; SBP, systolic blood 
pressure; TE, thromboembolism; TIA, transient ischemic attack; * the number of 
patients with available data
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Table 2. CHA2DS2-VASc and CHADS2 scores for the whole cohort and by sex 
 Total Males Females  p- value 
CHA2DS2-VASc Score 
Median (IQR)* 3.0 (2.0-4.0) 3.0 (1.0-4.0) 4.0 (3.0-5.0) <0.0001 
Male=0 or female=1 191(7.8) 122(8.9) 69(6.5) 
0.009 Male=1 or female=2 384(15.7) 233(16.9) 151(14.2) 
Male≥2 or female≥3 1867(76.5) 1021(74.2) 846(79.4) 
CHADS2 Score 
Median (IQR)* 2.0 (1.0-3.0) 2.0 (1.0-3.0) 2.0 (1.0-3.0) <0.0001 
CHADS2=0/1 subdivided by CHA2DS2-VASc 
CHADS2=0 and CHA2DS2-VASc=1 161(6.6) 92(6.7) 69(6.5) 
<0.0001 
CHADS2=0 and CHA2DS2-VASc≥2 76(3.1) 7(0.5) 69(6.5) 
CHADS2=1 and CHA2DS2-VASc=1 141(5.8) 141(10.2) 0(0.0) 
CHADS2=1 and CHA2DS2-VASc≥2 
 
533(21.8) 
 
256(18.6) 
 
277(26.0) 
 
*Mann-Whitney U test  
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Table 3. Antithrombotic therapy for patients discharged alive overall and by sex 
N (%) 
Total 
(n=2389) 
Males 
(n=1344) 
Females 
(n=1045) 
P value 
Warfarin use-Before Admission 174 (7.3) 98 (7.3) 76 (7.3) 1.00 
Warfarin use-During 
hospitalization 
791 (33.3) 428 (32.1) 363 (35.0) 0.09 
Aspirin 930 (38.9) 517 (38.5) 413 (39.5) 0.61 
Clopidogrel 
 
256 (10.7) 
 
155 (11.5) 
 
101 (9.7) 
 
0.16 
 
ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker 
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Table 4. In-hospital outcomes for the whole cohort and by sex 
 Total Males Females  P value 
In-hospital outcomes 
Inpatient ischemic stroke 283 (11.6) 153 (11.1) 130 (12.2) 0.41 
Inpatient major bleeding 80 (3.3) 54 (3.9) 26 (2.4) 0.05 
Inpatient death 53 (2.2) 32 (2.3) 21 (2.0) 0.58 
Length of stay, Median (IQR)*  10 (7-14) 10 (7-14) 10 (7-14) 0.80 
Length of stay >10 days, n (%) 
 
1077 (44.4) 
 
606 (44.3) 
 
471 (44.5) 
 
0.93 
 
 
*Mann-Whitney U test
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Table 5 Multivariate analyses for risk factors associated with inpatient mortality 
by sex  
 
 
 
 
 
 
 
 
TE, thromboembolism; TIA, transient ischemic attack;  
  
 Males Females  
 OR (95% CI) P value OR (95% CI) P value 
Age 
1.06 (1.02-1.11) 0.004 
1.02 (0.97-1.07) 0.40 
Hypertension 1.00 (0.48-2.12) 1.00 0.35 (0.14-0.88) 0.03 
Heart failure 0.40 (0.15-1.05) 0.06 1.44 (0.56-3.71) 0.46 
Diabetes - 1.00 0.93 (0.21-4.19) 0.93 
Previous ischemic 
Stroke/TIA/TE 
1.81 (1.25-2.63) 0.002 2.27 (1.43-3.61) <0.0001 
Coronary artery 
disease 
2.02 (0.90-4.54) 0.09 2.09 (0.72-6.08) 0.18 
Peripheral 
arterial disease 
0.63 (0.08-4.85) 0.65 
5.75 (1.49-22.16) 0.01 
Chronic Renal 
disease 
1.80 (0.52-6.21) 0.35 
5.68 (1.46-22.13) 0.01 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
24 
 
Figure 1. Flow chart of the study cohort recruitment 
 
